Interaction of Quindoline Derivative with Telomeric Repeat-Containing RNA Induces Telomeric DNA-damage Response in Cancer Cells Through Inhibition of Telomeric Repeat Factor 2
Yan Zhang,Deying Zeng,Jiaojiao Cao,Mingxue Wang,Bing Shu,Guotao Kuang,Tian-Miao Ou,Jia-Heng Tan,Lian-Quan Gu,Zhi-Shu Huang,Ding Li
DOI: https://doi.org/10.1016/j.bbagen.2017.09.015
IF: 4.117
2017-01-01
Biochimica et Biophysica Acta (BBA) - General Subjects
Abstract:Background: Telomeric repeat-containing RNA (TERRA) is a large non-coding RNA in mammalian cells, which forms an integral component of telomeric heterochromatin. TERRA can bind to an allosteric site of telomeric repeat factor 2 (TRF2), a key component of Shelterin that protect chromosome termini. Both TERRA and TRF2 have been recognized as promising new therapeutic targets for cancer treatment. Methods: Our methods include FRET assay, SPR, CD, microscale thermophoresis (MST), enzyme-linked immunosorbent assay (ELISA), chromatin immunoprecipitation (ChIP), colony formation assays, Western blot, immunofluorescence, cell cycle arrest and apoptosis detection, and xCELLigence real-time cell analysis (RTCA). Results: In our routine screening of small molecule libraries, we found that a Quindoline derivative, CK1-14 could bind to and stabilize TERRA G-quadruplex structure, which could bind more tightly with an allosteric site of a telomeric binding protein TRF2, resulting in dissociation of TRF2 from telomeric DNA. Further in cellular studies indicated that the above effect of CK1-14 on TERRA G-quadruplex could activate DNA-damage response and cause cell cycle arrest, resulting in inhibition of U2OS cell proliferation and causing cell apoptosis. Conclusions: Our mechanistic studies indicated that interaction of CK1-14 with TERRA induces telomeric DNA damage response in U2OS cancer cells through inhibition of TRF2. CK1-14 could be further developed as a promising lead compound targeting telomere for cancer treatment.